Side-by-side research comparison of Ipamorelin and MK-677 across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 36 on Ipamorelin and 57 on MK-677.
| Ipamorelin | MK-677 | |
|---|---|---|
| Drug class | ghrh secretagogue, ghrelin mimetic | n/a |
| Studies in corpus | 36 | 57 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 6 preclinical animal · 16 in vitro · 3 rct · 2 review · 1 | rct · 10 other · 10 review · 5 preclinical animal · 20 in vitro · 4 case report · 1 |
| Studies with explicit sample size | 3 | 8 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Ipamorelin and MK-677 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 2113 Ipamorelin batches across 690 manufacturers, 99.5% avg purity.
We tested 68 MK-677 batches across 31 manufacturers, 98.6% avg purity.
We hold deeper lab coverage on Ipamorelin (2113 batches tested). Ipamorelin edges ahead on average measured purity (99.5% vs 98.6%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Ipamorelin and MK-677 — the gold-standard direct comparison evidence.
**NN703 demonstrates that oral GH secretagogue therapy is pharmacologically viable**, with a 30% bioavailability and 4.1-hour half-life that are compatible with once-daily dosing — a profile ipamorelin itself cannot achieve orally. The divergent `GHS-R 1A` …
Looking for vendor-level purity, endotoxin, and HPLC data on Ipamorelin or MK-677? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.